Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption

References

• World Federation of Hemophilia. Types of Prophylaxis; 2014. Montréal, Québec. http://www.wfh.org/en/abd/prophylaxis/types-of-prophylaxis. Accessed August 2016
   Google Scholar
• Zappa S, McDaniel M, Marandola J, et al. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemoph Off World Fed Hemoph 2012;18:e140-53
   PubMed Web of Science ®Google Scholar
• Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemoph Off J World Fed Hemoph 2002;8:745-52
   PubMed Web of Science ®Google Scholar
• Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002;99:2337-41
   PubMed Web of Science ®Google Scholar
• Zanon E, Iorio A, Rocino A, et al. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemoph Off J World Fed Hemoph 2012;18:39-45
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). MASAC Documents #179 and #241; 2007. New York, USA. Available from: http://www.hemophilia.org/nhFweb/MainPgs/MainnhF.aspx?menuid=57&contentid =1007. Accessed March 10, 2014
   Google Scholar
• Geraghty S, Dunkley T, Harrington C, et al. Practice patterns in haemophilia A therapy – global progress towards optimal care. Haemoph Off J World Fed Hemoph 2006;12:75-81
   PubMed Web of Science ®Google Scholar
• De Moerloose P, Urbancik W, Van Den Berg HM, et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemoph Off J World Fed Hemoph 2008;14:931-8
   PubMed Web of Science ®Google Scholar
• du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemoph Off J World Fed Hemoph 2007;13:493-501
   PubMed Web of Science ®Google Scholar
• Schrijvers LH, Uitslager N, Schuurmans MJ, et al. Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemoph Off J World Fed Hemoph 2013;19:355-61
   PubMed Web of Science ®Google Scholar
• Duncan N, Kronenberger W, Roberson C, et al. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemoph Off J World Fed Hemoph 2010;16:247-55
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009;7:413-20
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Witkop ML, Lambing A, et al. Better adherence to prescribed treatment regimen is related to less chronic pain among adolescents and young adults with moderate or severe haemophilia. Haemophilia 2014;20:506-12. doi: 10.1111/hae.12360. Epub 2014 Feb 11
   PubMed Web of Science ®Google Scholar
• Krishnan S, Vietri J, Furlan R, et al. Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey. Haemoph Off J World Fed Hemoph 2015;21:64-70
   PubMed Web of Science ®Google Scholar
• Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemoph Off J World Fed Hemoph 2001;7:392-6
   PubMed Web of Science ®Google Scholar
• Schrijvers LH, Kars MC, Beijlevelt-van der Zande M, et al. Unravelling adherence to prophylaxis in haemophilia: a patients’ perspective. Haemophilia 2015;21:612-21. doi: 10.1111/hae.12660. Epub 2015 Apr 9.
   PubMed Web of Science ®Google Scholar
• Duncan N, Shapiro A, Ye X, et al. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemoph Off J World Fed Hemoph 2012;18:760-5
   PubMed Web of Science ®Google Scholar
• Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New Engl J Med 2013;369:2313-23
   PubMed Web of Science ®Google Scholar
• Biogen Hemophilia Inc. Data on file. Cambridge, MA: Biogen. 2013.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60
   PubMed Web of Science ®Google Scholar
• Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001;98:3600-6
   PubMed Web of Science ®Google Scholar
• Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemoph Off J World Fed Hemoph 2007;13:233-43
   PubMed Web of Science ®Google Scholar
• Valentino LA, Rusen L, Elezovic I, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014;20:398-406. doi: 10.1111/hae.12344. Epub 2014 Jan 13
   PubMed Web of Science ®Google Scholar
• Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemoph Off J World Fed Hemoph 2016;22:381-8
   PubMed Web of Science ®Google Scholar
• Windyga J, Lissitchkov T, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level </=2%) haemophilia B. Haemoph Off J World Fed Hemoph 2014;20:15-24
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Schwander B, Escudier B, et al. Indirect treatment comparison of bevacizumab + interferon-alpha-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. CEOR 2011;3:19-27
   Google Scholar
• Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012;10:359-67
   PubMed Web of Science ®Google Scholar
• Ho S, Gue D, McIntosh K, et al. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia. Haemoph Off J World Fed Hemoph 2014;20:39-43
   PubMed Web of Science ®Google Scholar